The overarching goal of our U54 Wellstone MD CRC is to pursue a biomarker-based research strategy that will further our understanding of the underlying pathophysiology of FSHD muscle weakness and enable development of animal models and therapeutic technologies for treatment of FSHD. Central to our research is a large repository of well-documented biomaterials from FSHD families, making possible statistically powered studies of the underlying molecular pathophysiology of FSHD and disease modifiers responsible for the clinical variability of this disease. This biorepository will be expanded to include blood, muscle and derived muscle progenitor cells from individuals with and without family history of disease along with 1st degree relatives who are classically affected and those without the FSHD allele as controls, to serve as resource for FSHD researchers worldwide and for three inter-related, collaborative Center projects. Center projects will utilize-state-of-the at genome sequencing, deep sequencing RNAseq and DNA methylation technologies to identify genetic and epigenetic modifiers and to identify disease biomarkers related to FSHD disease pathology and progression. Novel humanized mice and zebrafish models of FSHD will be exploited to better understand FSHD disease pathology and to develop disease specific therapies including gene and morpholino therapies. Center projects will be pursued by a reorganized group of 7 interactive investigators and their collaborators with complementary expertise in clinical medicine, genetics, molecular and cellular biology, and computational biology and genomics. An Educational and Training Core will provide hands-on research experience in FSHD clinical and basic research. An Administrative Core will partner with our primary patient advocacy group, the FSH Society, to organize regular WebX conferencing data-sharing meetings, FSHD workshops, patient-researcher networking meetings, and an annual retreat for Center investigators, trainees, NIH and the Center Advisory Committee to review current progress and develop new directions towards therapeutics for FSHD.

Public Health Relevance

FSHD is one of the most common forms of muscular dystrophy and yet the basic pathophysiology resulting in muscle weakness in the disorder is unknown. The proposed studies of FSHD disease biomarkers and disease modifiers undertake to reveal the underlying mechanisms responsible for the pathophyisiology of FSHD and to develop disease models for preclinical studies to develop FSHD therapeutics.

National Institute of Health (NIH)
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZNS1-SRB-S (57))
Program Officer
Urv, Tiina K
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Massachusetts Medical School Worcester
United States
Zip Code
Zhang, Yuanfan; King, Oliver D; Rahimov, Fedik et al. (2014) Human skeletal muscle xenograft as a new preclinical model for muscle disorders. Hum Mol Genet 23:3180-8
Mitsuhashi, Hiroaki; Mitsuhashi, Satomi; Lynn-Jones, Taylor et al. (2013) Expression of DUX4 in zebrafish development recapitulates facioscapulohumeral muscular dystrophy. Hum Mol Genet 22:568-77
Rahimov, Fedik; Kunkel, Louis M (2013) The cell biology of disease: cellular and molecular mechanisms underlying muscular dystrophy. J Cell Biol 201:499-510
Homma, Sachiko; Chen, Jennifer C J; Rahimov, Fedik et al. (2012) A unique library of myogenic cells from facioscapulohumeral muscular dystrophy subjects and unaffected relatives: family, disease and cell function. Eur J Hum Genet 20:404-10
Homma, Sachiko; Beermann, Mary Lou; Miller, Jeffrey Boone (2011) Peripheral nerve pathology, including aberrant Schwann cell differentiation, is ameliorated by doxycycline in a laminin-?2-deficient mouse model of congenital muscular dystrophy. Hum Mol Genet 20:2662-72
Reed, Patrick W; Bloch, Robert J (2011) Crystallin-gazing: unveiling enzymatic activity. J Neurochem 118:315-6
Roche, Joseph A; Ford-Speelman, Diana L; Ru, Lisa W et al. (2011) Physiological and histological changes in skeletal muscle following in vivo gene transfer by electroporation. Am J Physiol Cell Physiol 301:C1239-50
Rahimov, Fedik; King, Oliver D; Warsing, Leigh C et al. (2011) Gene expression profiling of skeletal muscles treated with a soluble activin type IIB receptor. Physiol Genomics 43:398-407
Arashiro, Patricia; Eisenberg, Iris; Kho, Alvin T et al. (2009) Transcriptional regulation differs in affected facioscapulohumeral muscular dystrophy patients compared to asymptomatic related carriers. Proc Natl Acad Sci U S A 106:6220-5
Vishnudas, Vivek K; Miller, Jeffrey Boone (2009) Ku70 regulates Bax-mediated pathogenesis in laminin-alpha2-deficient human muscle cells and mouse models of congenital muscular dystrophy. Hum Mol Genet 18:4467-77